VIR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Vir Biotechnology Inc (VIR) is not a strong buy at the moment for a beginner investor with a long-term focus. While the company has positive catalysts such as promising clinical data and analyst upgrades, the technical indicators, options sentiment, and financial performance suggest caution. The stock is better suited for monitoring rather than immediate investment.
The technical indicators show a neutral to slightly bearish trend. The MACD is below 0 and negatively contracting, RSI is neutral at 44.382, and the stock is trading near its support levels (S1: 8.661). Moving averages are converging, indicating indecision in the market.
Analysts have significantly raised price targets, citing strong Phase 1 data for VIR-5500 and a lucrative partnership with Astellas. The company's gross margin has also improved YoY, and its oncology pipeline shows promise.
Hedge funds are selling heavily, with a 3690.48% increase in selling activity. Financial performance in Q4 2025 shows a significant drop in net income (-58.96% YoY) and EPS (-59.21% YoY), which may deter long-term investors. No recent news or congress trading data to support a bullish sentiment.
In Q4 2025, revenue increased by 417.78% YoY to $64.07M, but net income dropped to -$42.92M (-58.96% YoY), and EPS fell to -$0.31 (-59.21% YoY). Gross margin improved to 99.96%, up 5.81% YoY.
Analysts are bullish, with multiple upgrades and price target increases ranging from $17 to $30. The consensus highlights strong clinical data and a promising oncology pipeline. However, the stock's current price of $8.89 is far below these targets, indicating potential upside but also risks.
